DAN0 logo

DanCann Pharma A/SDB:DAN0 Stock Report

Market Cap €5.3m
Share Price
n/a
1Yn/a
7D0%
1D-1.7%
Portfolio Value
​
View

DanCann Pharma A/S

DB:DAN0 Stock Report

Market Cap: €5.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DanCann Pharma (DAN0) Stock Overview

A biopharmaceutical company, focuses on commercializing new therapeutic cannabinoids in various disease areas. More details

DAN0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap (€40M)

Has less than 1 year of cash runway

Earnings have declined by 24.8% per year over past 5 years

Highly volatile share price over the past 3 months compared to the German market

+ 1 more risk

DAN0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW437,855 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
437,855 investors already sharing narratives
View all narratives

DanCann Pharma A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for DanCann Pharma
Historical stock prices
Current Share PriceDKK 0.029
52 Week HighDKK 0.40
52 Week LowDKK 0.011
Beta1.91
1 Month Change-7.81%
3 Month Change68.57%
1 Year Changen/a
3 Year Change-99.90%
5 Year Changen/a
Change since IPO-99.90%

Recent News & Updates

Recent updates

Shareholder Returns

DAN0DE PharmaceuticalsDE Market
7D0%-3.0%-2.1%
1Yn/a38.4%3.6%

Return vs Industry: Insufficient data to determine how DAN0 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how DAN0 performed against the German Market.

Price Volatility

Is DAN0's price volatile compared to industry and market?
DAN0 volatility
DAN0 Average Weekly Movement55.5%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement5.1%
10% most volatile stocks in DE Market12.6%
10% least volatile stocks in DE Market2.6%

Stable Share Price: DAN0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: DAN0's weekly volatility has decreased from 65% to 55% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20185Jeppe Rasmussenwww.dancann.com

DanCann Pharma A/S, a biopharmaceutical company, focuses on commercializing new therapeutic cannabinoids in various disease areas. The company distributes prescription cannabinoid-based medicines. It develops EXT03 CannGros, an oral extract based on Bediol; EXT04 CannGros, an oral extract based on Bedrolite; EXT02 CannGros, an oral extract based on Bedrocan; FLS04 CannGros granulate; FLS05 CannGros flos; and OTC01 CannGros, OTC02 CannGros, and OTC03 CannGros extracts.

DanCann Pharma A/S Fundamentals Summary

How do DanCann Pharma's earnings and revenue compare to its market cap?
DAN0 fundamental statistics
Market cap€5.33m
Earnings (TTM)-€1.33m
Revenue (TTM)€535.97k
0.1x
P/S Ratio
-0.1x
P/E Ratio

Is DAN0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DAN0 income statement (TTM)
RevenueDKK 4.01m
Cost of RevenueDKK 7.09m
Gross Profit-DKK 3.08m
Other ExpensesDKK 6.90m
Earnings-DKK 9.98m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.50
Gross Margin-76.76%
Net Profit Margin-248.89%
Debt/Equity Ratio0%

How did DAN0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/27 11:27
End of Day Share Price 2026/01/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DanCann Pharma A/S is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Markus AugustssonCarlsquare AB
Jonatan AnderssonCarlsquare AB
Fredrik NilssonCarlsquare AB